AstraZeneca plc vs Charter Communications Inc — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Charter Communications Inc trades at $150.3 (market cap $18.81B). The key difference: AstraZeneca plc is far larger — about 13.2× Charter Communications Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| AZN | CHTR | |
|---|---|---|
Market Cap | $248.14B | $18.81B |
Sector | Health | Media |
52-Week High | $209.48 | $282.74 |
52-Week Low | $147.06 | $123.31 |
Enterprise Value | $275.41B | $115.01B |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Charter Communications (CHTR) trades at $153.29, up 0.47% today, near its pivot point of $152. The stock shows mixed technical signals with a bullish moving average trend but bearish oscillators. Fundamentally, it trades at low valuation multiples (P/E 4.1, P/S 0.37) with solid profitability (ROE 29.7%, net margin 9.05%), though Q1 2026 earnings missed expectations. Recent news highlights debt refinancing activities and competitive pressures in broadband.
Outlook: CHTR presents a value opportunity with deep discount to historical multiples, supported by strong cash flow and buybacks, but faces headwinds from subscriber losses and high debt load. Risks include fiber competition and revenue declines, while analyst consensus leans bullish with a $166.18 price target.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →